# FDA WARNING_LETTER - Jilin Shulan Synthetic Pharmaceutical Co. Ltd. - November 10, 2017

Source: https://www.globalkeysolutions.net/records/warning_letter/jilin-shulan-synthetic-pharmaceutical-co-ltd/065f5375-0619-4435-b40e-1b83311b9692

> FDA WARNING_LETTER for Jilin Shulan Synthetic Pharmaceutical Co. Ltd. on November 10, 2017. Product: Drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: WARNING_LETTER
- Company Name: Jilin Shulan Synthetic Pharmaceutical Co. Ltd.
- Inspection Date: 2017-11-10
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research
- Summary: On May 14, 2018, the FDA issued a Warning Letter to Jilin Shulan Synthetic Pharmaceutical Co., Ltd. following an inspection from November 7-10, 2017. The inspection revealed significant deviations from current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (API), rendering their API adulterated.

Key violations include:
1. **Failure to document and investigate deviations and OOS results:** An undocumented manufacturing deviation was found, and dual sets of laboratory records for multiple batches showed uninvestigated Out-of-Specification (OOS) results, with passing results lacking supporting evidence. The firm's response regarding OOS was inadequate.
2. **Insufficient controls over computerized systems:** Audit trails were not enabled on instruments, electronic data backups were unsecured, and operators had full system permissions, including the ability to modify and delete files.
3. **Failure to record activities contemporaneously:** Examples included pre-signed, blank, or partially completed batch records, and data changes in pencil without justification.

The FDA noted that the firm's quality unit lacked sufficient authority and resources. The letter strongly recommended retaining a qualified consultant for remediation. Required corrective actions include a comprehensive investigation into data inaccuracies, a risk assessment of failures on drug quality, and a detailed management strategy with corrective and preventive actions, root cause analysis, and interim/long-term measures.

The firm was placed on Import Alert 66-40

## Related Documents

- [483 - 2026-11-07](https://www.globalkeysolutions.net/records/483/jilin-shulan-synthetic-pharmaceutical-co-ltd/61b255fc-1046-4e28-8fa5-0592cb64616c)

## Related Officers

- [Director](https://www.globalkeysolutions.net/people/francis-godwin/1556d203-d47c-4744-af37-2591a163149e)

Company: https://www.globalkeysolutions.net/companies/jilin-shulan-synthetic-pharmaceutical-co-ltd/c7182328-88a3-48b2-8be3-1660603b27b3

Office: https://www.globalkeysolutions.net/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c